SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Pharmos (PARS)
An SI Board Since October 1998
Posts SubjectMarks Bans Symbol
1386 42 0 PARS
Emcee:  Dr. John M. de Castro Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1211Up 56% on volume of 5.5 million shares, and no news from the company. Anybody? LJorgen Jensen-6/10/2003
1210I think you are right. There has been no news from the company and the posts on Tony van Werkhooven-4/28/2003
1209PARS has fairly heavy trading on the upside these last days. Yet, from my readiLLLefty-4/28/2003
1208Sooo early for both it's not worth researching. And for PARS it may only bekeokalani'nui-4/22/2003
1207Any chance this may infringe any of PARS' stuff? I guess even if it didn'fred hayes-4/22/2003
1206Buried in Novartis's annual report: "Several promising compounds alreakeokalani'nui-4/22/2003
1205Pharmos Corporation Reports 2002 Results Cost Containment Program Tightens 2003 leigh aulper-3/7/2003
1204CEOCAst newsletter Sunday, December 8 2002 laup789@aol.com ----------------leigh aulper-12/9/2002
1203Pharmos Corporation (NASDAQ: PARS) $1.32 Thanks for post but would appreciate sLLLefty-12/9/2002
1202Pharmos Corporation (NASDAQ: PARS) $1.32 One of the most severely depressed secleigh aulper-12/9/2002
1201Pharmos Files Investigational New Drug Application for A Phase III Study of Dexaleigh aulper-10/21/2002
1200Pharmos to Start Clinical Trial of Dexanabinol in Heart Surgery Patients PR NEWSleigh aulper-7/25/2002
1199Pharmos Corporation Reports 2001 Results Sale of Ophthalmic Business Results in leigh aulper-3/7/2002
1198Israel's Pharmos brain injury drug tests start TEL AVIV, Nov 29 (Reuters) - leigh aulper-11/29/2001
1197Pharmos Compounds Demonstrate Neuroprotection in Stroke and Parkinson's Diseleigh aulper-11/12/2001
1196Pharmos Reports 2001 Third Quarter and Nine Month Results; Progress Noted in Phaleigh aulper-11/6/2001
1195In selling its only revenue-producing drugs, I guess it means cearly PARS is goiLLLefty-10/15/2001
1194Pharmos Corporation Sells Ophthalmic Products to Bausch & Lomb Proceeds to Fleigh aulper-10/10/2001
1193Natural Compound May Reduce Brain Trauma Damage By Melissa Schorr NEW YORK (Reukeokalani'nui-10/4/2001
1192Pharmos' Traumatic Brain Injury Trial of Dexanabinol Expands into U.K. ISELIleigh aulper-9/19/2001
1191Cacaito Thanks for the info. RichRich-8/29/2001
1190"I suspect we’ll get a good chuck of pts out of Germany (not only because oCacaito-8/29/2001
1189Pharmos Reports 2001 Second Quarter and Six Month Results ISELIN, N.J., Aug. 6 /leigh aulper-8/6/2001
1188Pharmos to Review Status of Pipeline at Annual Meeting ISELIN, N.J., July 10 /PRleigh aulper-7/10/2001
1187Is Cremophor still part of the dexanabinol drug formulation? Pharmos was (is?)Cacaito-6/19/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News